FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094544723> ?p ?o ?g. }

• W3094544723 endingPage "1555" @default.
• W3094544723 startingPage "1554" @default.
• W3094544723 abstract "In their case series reporting experience from a single center of the first 10 patients with coronavirus disease 2019 (COVID-19) to receive venovenous extracorporeal membrane oxygenation (VV-ECMO), Usman et al.1Usman AA Han J Acker A et al.A case series of devastating intracranial hemorrhage during venovenous extracorporeal membrane oxygenation for COVID-19.J Cardiothorac Vasc Anesth. 2020; 34: 3006-3012Abstract Full Text Full Text PDF PubMed Scopus (35) Google Scholar described significant clinical challenges managing anticoagulation. Four (40%) suffered intracerebral hemorrhage (ICH), three (30%) of which led to death. They advised caution in the anticoagulation of COVID-19 patients undergoing VV-ECMO, and that heparin is monitored actively and frequently. Although we agree that COVID-19 presents new challenges for centers providing VV-ECMO, we wish to comment on some of the limitations of their study in the context of our own experiences. This will. hopefully, set out some of our own experiential learning, as well as aid in the interpretation of their case series and its applicability to future practice. First, the number of patients included means our ability to draw any conclusions about the rate of ICH in similar, larger populations from these data is extremely limited. Although the authors acknowledge this, we wish to provide further mathematical rationale. It is possible to determine the 95% confidence interval of the proportion of those who died (30%) as 12% to 74%. This is a simple mathematical transformation of a nominator/denominator combination and is simply a way of incorporating sample size into any calculated proportion. A small sample size results in a wide confidence interval. It can be shown by simulating these calculations for different sample sizes that the confidence interval of any proportion is extremely sensitive to n when n is below 50, irrespective of the event rate.2Pandit JJ If it hasn't failed, does it work? On ‘the worst we can expect’ from observational trial results, with reference to airway management devices.Anaesthesia. 2012; 67: 578-583Crossref PubMed Scopus (62) Google Scholar As such, these data are useful, but the true rate of fatal ICH in patients with COVID-19 undergoing VV-ECMO may be much higher or even lower than that shown by Usman et al. Second, the authors described the use of activated partial thromboplastin time (APTT) as the sole measure of effectiveness of anticoagulation with heparin but did not mention using any other laboratory measure. There is considerable evidence of discordance between anti-factor Xa levels (which arguably better reflects heparin effect) and APTT,3Takemoto CM Streiff MB Shermock KM et al.Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: Biochemical basis for discordance.Am J Clin Pathol. 2013; 139: 450-456Crossref PubMed Scopus (73) Google Scholar and the use of anti-factor Xa levels alongside APTT or as a lone measure may allow for more nuanced tailoring of anticoagulation strategies, especially in the context of COVID-19.4Bowles L Platton S Yartey N et al.Lupus anticoagulant and abnormal coagulation tests in patients with covid-19.N Engl J Med. 2020; 383: 288-290Crossref PubMed Scopus (345) Google Scholar For patients with COVID-19, a prolonged APTT may indicate a specific or nonspecific clotting factor deficiency, and the presence of lupus anticoagulant, which is an indirect deficiency and not associated with bleeding, may affect in vitro tests of anticoagulation. The presence of lupus anticoagulant and a discordance between APTT and anti-factor Xa levels for patients receiving intravenous unfractionated heparin was a common finding at our center for patients with COVID-19 on VV-ECMO. At the beginning of the pandemic and before we understood the limitations of APTT monitoring in COVID-19, we were more aggressive with anticoagulation due to concerns about severe thromboembolic disease, with a starting dose of 1,000 U/hr of unfractionated intravenous heparin titrated upward incrementally according to the APTT. A few early patients developed fatal ICHs, which led to a more conservative strategy of 250 U/hr titrated incrementally to a maximum of 1,000 U/hr with twice daily anti-factor Xa levels for titration. All heparin dosing prescriptions and changes were made on a case-by-case basis and according to the overall clinical picture, usually after discussion among two or more consultants. We had one heparin-free run of 60 days due to airway bleeding and experienced no associated circuit problems with this case and other heparin-free/sparse runs. Third, regarding the wider disease process, the authors described issues with extracorporeal thrombosis and specifically, oxygenator failure. Since the start of the COVID-19 pandemic and with 37 patients treated, we have not seen an oxygenator or pump failure due to thrombosis, and certainly not to the extent described by Usman et al. However, we have found venovenous hemofiltration to be an issue, with the circuits clotting off at a higher rate than we would normally expect. This runs alongside another issue not addressed by the authors—what to do in patients presenting with thromboembolic disease, such as pulmonary embolism (present in up to 30% of patients), more so when there is radiologic evidence of ICH.5Thachil J Agarwal S. Understanding the COVID-19 coagulopathy spectrum [e-pub ahead of print].Anaesthesia. 2020; (Accessed October 9, 2020)https://doi.org/10.1111/anae.15141Crossref PubMed Scopus (35) Google Scholar If pulmonary embolic disease is a contributor to respiratory failure before ECMO, decisions about anticoagulation strategies have no easy answers. Such pathology might be seen on a whole-body computed tomography (CT) scan and we decided, early in the pandemic, to undertake interval CT scans after admission and throughout the ECMO run. Although not without risk, this was an extremely beneficial strategy to enable individual decisions to be made about anticoagulation, and we saw our ICH rate reduce as a result. Finally, in our own experience as a regional ECMO center for the North West of the United Kingdom, we had 37 patients (again, with n < 50 it is difficult to generalize our experiences) with COVID-19 undergo VV-ECMO. Of these, 14 (37.8%) were discharged home and 23 (62.2%) have died. Eight (21.7%) had ICHs, of which five (13.5%) were fatal. We did not see any cases of heparin-induced thrombocytopenia in patients with COVID-19, which is usually a common occurrence (∼5%) during non-COVID-19 VV-ECMO. The reasons for this are not yet known, but when heparin-induced thrombocytopenia was suspected clinically due to, for example, a relative or absolute decrease in platelet count, we retained a high degree of suspicion and tested for it. We did not experience problems with circuitry and/or oxygenators, in contrast to the authors who described 10 circuit changes in their 10 patients, nine of which were due to oxygenator clots. Perhaps the type of equipment is important, and the magnetic levitating centrifugal pump systems we use may be associated with less thrombogenesis.6Bemtgen X Zotzmann V Benk C et al.Thrombotic circuit complications during venovenous extracorporeal membrane oxygenation in COVID-19.J Thromb Thrombolysis. 2020; (Accessed October 9, 2020)https://doi.org/10.1007/s11239-020-02217-1Crossref Scopus (49) Google Scholar We also have accumulated much clinical experience with the dynamic nature of cerebral compromise associated with VV-ECMO in patients with COVID-19. We have seen subarachnoid hemorrhage, isolated intracranial hemorrhages and posterior reversible encephalopathy syndrome, sometimes in the same patient. There always should be hope for patients who develop ICH, as one case of a large ICH almost completely resolved by the end of the run, after which hospital discharge ensued. Overall, Usman et al. should be congratulated for their detailed analysis during a difficult time at the start of the pandemic, but there is now an urgent need for the analysis and publication of larger registry datasets to reveal the true incidence of problems associated with anticoagulation, together with a consensus approach on how best to tailor anticoagulation strategies for individual patients. Our understanding of the neurologic and hematologic sequalae of VV-ECMO in patients with COVID-19 is at a very early stage and we hope we can continue to add to this understanding by learning from each other through collaboration and data sharing among centers. No funding or conflicts of interest to declare. A Case Series of Devastating Intracranial Hemorrhage During Venovenous Extracorporeal Membrane Oxygenation for COVID-19Journal of Cardiothoracic and Vascular AnesthesiaVol. 34Issue 11PreviewAnticoagulation may be a challenge in coronavirus disease 2019 (COVID-19) extracorporeal membrane oxygenation due to endothelial injury and dysregulation of coagulation, which may increase the risk of thrombotic and bleeding complications. This report was created to describe the authors’ single institutional experience, with emphasis on the high rate of intracranial hemorrhage for the first 10 patients with COVID-19 placed on venovenous extracorporeal membrane oxygenation (VV ECMO). Full-Text PDF" @default.
• W3094544723 created "2020-10-29" @default.
• W3094544723 creator A5003098177 @default.
• W3094544723 creator A5012743329 @default.
• W3094544723 creator A5028930910 @default.
• W3094544723 creator A5050011126 @default.
• W3094544723 creator A5068591963 @default.
• W3094544723 date "2021-05-01" @default.
• W3094544723 modified "2023-10-11" @default.
• W3094544723 title "Anticoagulation Strategies and Determining the Rate of Fatal Intracerebral Hemorrhage Associated With Venovenous Extracorporeal Membrane Oxygenation in Patients With Coronavirus Disease 2019" @default.
• W3094544723 cites W2045196652 @default.
• W3094544723 cites W2128844712 @default.
• W3094544723 cites W3023452186 @default.
• W3094544723 cites W3026409248 @default.
• W3094544723 cites W3042035358 @default.
• W3094544723 cites W3045475816 @default.
• W3094544723 doi "https://doi.org/10.1053/j.jvca.2020.10.039" @default.
• W3094544723 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7584492" @default.
• W3094544723 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33189536" @default.
• W3094544723 hasPublicationYear "2021" @default.
• W3094544723 type Work @default.
• W3094544723 sameAs 3094544723 @default.
• W3094544723 citedByCount "3" @default.
• W3094544723 countsByYear W30945447232021 @default.
• W3094544723 countsByYear W30945447232022 @default.
• W3094544723 countsByYear W30945447232023 @default.
• W3094544723 crossrefType "journal-article" @default.
• W3094544723 hasAuthorship W3094544723A5003098177 @default.
• W3094544723 hasAuthorship W3094544723A5012743329 @default.
• W3094544723 hasAuthorship W3094544723A5028930910 @default.
• W3094544723 hasAuthorship W3094544723A5050011126 @default.
• W3094544723 hasAuthorship W3094544723A5068591963 @default.
• W3094544723 hasBestOaLocation W30945447231 @default.
• W3094544723 hasConcept C116675565 @default.
• W3094544723 hasConcept C126322002 @default.
• W3094544723 hasConcept C159047783 @default.
• W3094544723 hasConcept C164705383 @default.
• W3094544723 hasConcept C177713679 @default.
• W3094544723 hasConcept C2776858399 @default.
• W3094544723 hasConcept C2777094939 @default.
• W3094544723 hasConcept C2777648638 @default.
• W3094544723 hasConcept C2777736543 @default.
• W3094544723 hasConcept C2779134260 @default.
• W3094544723 hasConcept C3006700255 @default.
• W3094544723 hasConcept C3007834351 @default.
• W3094544723 hasConcept C3008058167 @default.
• W3094544723 hasConcept C42219234 @default.
• W3094544723 hasConcept C524204448 @default.
• W3094544723 hasConcept C70289976 @default.
• W3094544723 hasConcept C71924100 @default.
• W3094544723 hasConceptScore W3094544723C116675565 @default.
• W3094544723 hasConceptScore W3094544723C126322002 @default.
• W3094544723 hasConceptScore W3094544723C159047783 @default.
• W3094544723 hasConceptScore W3094544723C164705383 @default.
• W3094544723 hasConceptScore W3094544723C177713679 @default.
• W3094544723 hasConceptScore W3094544723C2776858399 @default.
• W3094544723 hasConceptScore W3094544723C2777094939 @default.
• W3094544723 hasConceptScore W3094544723C2777648638 @default.
• W3094544723 hasConceptScore W3094544723C2777736543 @default.
• W3094544723 hasConceptScore W3094544723C2779134260 @default.
• W3094544723 hasConceptScore W3094544723C3006700255 @default.
• W3094544723 hasConceptScore W3094544723C3007834351 @default.
• W3094544723 hasConceptScore W3094544723C3008058167 @default.
• W3094544723 hasConceptScore W3094544723C42219234 @default.
• W3094544723 hasConceptScore W3094544723C524204448 @default.
• W3094544723 hasConceptScore W3094544723C70289976 @default.
• W3094544723 hasConceptScore W3094544723C71924100 @default.
• W3094544723 hasIssue "5" @default.
• W3094544723 hasLocation W30945447231 @default.
• W3094544723 hasLocation W30945447232 @default.
• W3094544723 hasLocation W30945447233 @default.
• W3094544723 hasOpenAccess W3094544723 @default.
• W3094544723 hasPrimaryLocation W30945447231 @default.
• W3094544723 hasRelatedWork W1963989287 @default.
• W3094544723 hasRelatedWork W1994000525 @default.
• W3094544723 hasRelatedWork W2057359511 @default.
• W3094544723 hasRelatedWork W2165627064 @default.
• W3094544723 hasRelatedWork W2323408176 @default.
• W3094544723 hasRelatedWork W2766554683 @default.
• W3094544723 hasRelatedWork W2890448044 @default.
• W3094544723 hasRelatedWork W2899478397 @default.
• W3094544723 hasRelatedWork W3171115865 @default.
• W3094544723 hasRelatedWork W3215766299 @default.
• W3094544723 hasVolume "35" @default.
• W3094544723 isParatext "false" @default.
• W3094544723 isRetracted "false" @default.
• W3094544723 magId "3094544723" @default.
• W3094544723 workType "article" @default.